Compositions and methods for inhibiting expression of Eg5 and VEGF genes

Details for Australian Patent Application No. 2009221775 (hide)

Owner Alnylam Pharmaceuticals, Inc.

Inventors Bumcrot, David; Sah Dinah, Wen-Yee; Toudjarska, Ivanka

Agent Griffith Hack

Pub. Number AU-A-2009221775

PCT Pub. Number WO2009/111658

Priority 61/034,019 05.03.08 US; 61/086,381 05.08.08 US; 61/150,664 06.02.09 US; 61/112,079 06.11.08 US; 61/083,367 24.07.08 US

Filing date 5 March 2009

Wipo publication date 11 September 2009

International Classifications

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

Event Publications

21 October 2010 PCT application entered the National Phase

  PCT publication WO2009/111658 Priority application(s): WO2009/111658

4 November 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 30 Sep 2010

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009221778-Molecular diagnosis and classification of malignant melanoma

2009221774-Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site